benzo[b]thiophen-3-yl 4-methoxyphenyl ether | 193964-34-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: benzo[b]thiophen-3-yl 4-methoxyphenyl ether
• 英文别名: 3-(4-methoxyphenoxy)benzo[b]thiophene；3-(p-methoxyphenoxy)benzo[b]thiophene；3-(4-methoxyphenoxy)-1-benzothiophene
• CAS: 193964-34-0
• 化学式: C₁₅H₁₂O₂S
• 分子量: 256.325
• InChiKey: MOONLSZHTADEJJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  46.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  benzo[b]thiophen-3-yl 4-methoxyphenyl ether 在 I2 、 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 以143 mg (0.37 mmol; 72%)的产率得到2-iodobenzo[b]thiophen-3-yl 4-methoxyphenyl ether
  参考文献：
  名称：

  Antithrombotic diamines

  摘要：

  该应用涉及将I式中所定义的二胺用作凝血酶抑制剂、凝血抑制剂和血栓栓塞性疾病药剂。它还提供了I式的新化合物，其制备方法和中间体，以及包含这些新化合物的药物配方。

  公开号：

  US06025382A1
• 作为产物：
  描述：

  3-溴苯并噻吩亚砜 在 二异丁基氢化铝 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 20.0h， 生成 benzo[b]thiophen-3-yl 4-methoxyphenyl ether
  参考文献：
  名称：

  Efficient Access to 2-Aryl-3-Substituted Benzo[b]thiophenes

  摘要：

  Benzo[b]thiophene derivatives are important in part because of their use as selective estrogen receptor modulators. They are usually synthesized by intramolecular cyclization. Here, we propose a method for the synthesis of 2-arylbenzo[b]thiophenes with heteroatoms at the 3-positions directly from the benzo [b]thiophene core by using an aromatic nucleophilic substitution reaction and Heck-type coupling. This methodology provides 2-aryl-3-amino or phenoxybenzo[b]thiophenes in about 35% overall yield in 5 steps.

  DOI：

  10.1021/jo0500378

文献信息

• Cu/Fe/O=PPh₃-Catalyzed Etherification for the Synthesis of Aryl 3-Benzo[<i>b</i>]thienyl Ethers
  作者：Koichi Mitsudo、Takuya Asada、Tomohiro Inada、Yuji Kurimoto、Hiroki Mandai、Seiji Suga

  DOI：10.1246/cl.180425

  日期：2018.8.5

  Cu/Fe-cocatalyzed cross-coupling reactions between 3-bromobenzo[b]thiophene and hydroxyaryls are described herein. The combination of Cu and Fe catalysts is important for the progress of the reacti...

  3-溴苯并[b]噻吩和羟基芳基之间的Cu/Fe共催化的交叉偶联反应在本文中有所描述。Cu和Fe催化剂的组合对于反应的进展很重要...
• Copper-Catalyzed Diaryl Ether Formation from (Hetero)aryl Halides at Low Catalytic Loadings
  作者：Yuntong Zhai、Xiaofei Chen、Wei Zhou、Mengyang Fan、Yisheng Lai、Dawei Ma

  DOI：10.1021/acs.joc.7b00493

  日期：2017.5.5

  Diaryl formation is achieved by coupling phenols and (hetero)aryl halides under the catalysis of CuI/N,N′-bis(2-phenylphenyl) oxalamide (BPPO) or CuI/N-(2-phenylphenyl)-N′-benzyl oxalamide (PPBO) at 90 °C using DMF or MeCN as the solvent. Only 0.2–2 mol % CuI and ligand are required for complete conversion, which represents the lowest catalytic loadings for a general Cu/ligand-catalyzed diaryl ether

  通过在CuI / N，N'-双（2-苯基苯基）草酰胺（BPPO）或CuI / N-（2-苯基苯基）-N'-苄基草酰胺的催化下偶联酚和（杂）芳基卤化物来形成二芳基（PPBO）在90°C下使用DMF或MeCN作为溶剂。完全转化仅需要0.2–2 mol％的CuI和配体，这代表了通常的Cu /配体催化的二芳基醚形成的最低催化负载量。
• A New Biarylphosphine Ligand for the Pd-Catalyzed Synthesis of Diaryl Ethers under Mild Conditions
  作者：Luca Salvi、Nicole R. Davis、Siraj Z. Ali、Stephen L. Buchwald

  DOI：10.1021/ol202955h

  日期：2012.1.6

  A new bulky biarylphosphine ligand (L8) has been developed that allows the Pd-catalyzed C–O cross-coupling of a wide range of aryl halides and phenols under milder conditions than previously possible. A direct correlation between the size of the ligand substituents in the 2′, 4′, and 6′ positions of the nonphosphine containing ring and the reactivity of the derived catalyst system was observed. Specifically

  已经开发出一种新的庞大的联芳基膦配体 ( L8 )，它允许在比以前更温和的条件下，Pd 催化的 C-O 交叉偶联广泛的芳基卤化物和苯酚。观察到含非膦环的 2'、4' 和 6' 位置的配体取代基的大小与衍生催化剂体系的反应性之间存在直接相关性。具体而言，偶联速率随着这些取代基的大小而增加。
• [EN] ANTITHROMBOTIC DIAMINES<br/>[FR] DIAMINES ANTITHROMBOTIQUES
  申请人：ELI LILLY AND COMPANY

  公开号：WO1997025033A1

  公开（公告）日：1997-07-17

  (EN) This application relates to the use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents of diamines of formula (I) as defined herein. It also provides novel compounds of formula (I), processes and intermediates for their preparation, and pharmaceutical formulations comprising the novel compounds of formula (I).(FR) La présente invention concerne l'utilisation, comme inhibiteurs de thrombine, inhibiteurs de coagulation et agents destinés aux désordres de la thromboembolie, de diamines de formule I telle qu'elle est définie dans la description. L'invention concerne aussi des composés nouveaux de formule I, des procédés et des produits intermédiaires pour leur préparation, et des formulations pharmaceutiques comprenant les composés nouveaux de formule I.

  该应用涉及使用公式（I）所定义的二胺作为凝血酶抑制剂、凝血抑制剂和血栓栓塞疾病药物的用途。它还提供了公式（I）的新化合物、其制备过程和中间体，以及包含公式（I）的新药物配方。
• Diamino Benzo[<i>b</i>]thiophene Derivatives as a Novel Class of Active Site Directed Thrombin Inhibitors. 5. Potency, Efficacy, and Pharmacokinetic Properties of Modified C-3 Side Chain Derivatives
  作者：Daniel J. Sall、Dianna L. Bailey、Jolie A. Bastian、John A. Buben、Nickolay Y. Chirgadze、Amy C. Clemens-Smith、Michael L. Denney、Matthew J. Fisher、Deborah D. Giera、Donetta S. Gifford-Moore、Richard W. Harper、Lea M. Johnson、Valentine J. Klimkowski、Todd J. Kohn、Ho-Shen Lin、Jefferson R. McCowan、Alan D. Palkowitz、Michael E. Richett、Gerald F. Smith、David W. Snyder、Kumiko Takeuchi、John E. Toth、Minsheng Zhang

  DOI：10.1021/jm9903388

  日期：2000.2.1

  A systematic investigation of the structure-activity relationships of the C-3 side chain of the screening hit la led to the identification of the potent thrombin inhibitors 23c, 28c, and 31c. Their activities (1240, 903, and 1271 x 10(6) L/mol, respectively) represent 2200- and 2900-fold increases in potency over the starting lead la. This activity enhancement was accomplished with an increase of thrombin selectivity. The in vitro anticoagulant profiles of derivatives 28c and 31c were determined, and they compare favorably with the clinical agent H-R-1-[4aS,-8aS]perhydroisoquinolyl-prolyl-arginyl aldehyde (D-Piq-Pro-Arg-H; 32). The more potent members of this series have been studied in an arterial/venous shunt (AV shunt) model of thrombosis and were found to be efficacious in reducing clot formation. However, their efficacy is currently limited by their rapid and extensive distribution following administration.